JPMorgan Chase & Co. Purchases 33,078 Shares of Cryoport, Inc. (NASDAQ:CYRX)

JPMorgan Chase & Co. boosted its holdings in Cryoport, Inc. (NASDAQ:CYRX) by 10.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 338,315 shares of the company’s stock after purchasing an additional 33,078 shares during the period. JPMorgan Chase & Co. owned about 0.68% of Cryoport worth $2,632,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. LPL Financial LLC increased its stake in shares of Cryoport by 1,366.1% in the fourth quarter. LPL Financial LLC now owns 436,766 shares of the company’s stock worth $3,398,000 after purchasing an additional 406,976 shares in the last quarter. Perkins Capital Management Inc. raised its position in shares of Cryoport by 1,286.1% in the fourth quarter. Perkins Capital Management Inc. now owns 159,400 shares of the company’s stock worth $1,240,000 after buying an additional 147,900 shares in the last quarter. Barclays PLC boosted its position in shares of Cryoport by 272.9% during the 3rd quarter. Barclays PLC now owns 81,417 shares of the company’s stock valued at $660,000 after acquiring an additional 59,582 shares during the last quarter. SG Americas Securities LLC grew its stake in Cryoport by 44.8% in the 4th quarter. SG Americas Securities LLC now owns 146,789 shares of the company’s stock worth $1,142,000 after buying an additional 45,430 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Cryoport by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,097,369 shares of the company’s stock valued at $8,902,000 after acquiring an additional 38,520 shares during the last quarter. Institutional investors own 92.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on CYRX. Roth Mkm reiterated a “buy” rating and set a $15.00 price target on shares of Cryoport in a research report on Tuesday, April 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Cryoport in a research note on Wednesday, April 16th. Guggenheim reissued a “buy” rating and issued a $10.00 target price on shares of Cryoport in a research note on Wednesday, April 16th. Finally, UBS Group increased their target price on Cryoport from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Cryoport has an average rating of “Moderate Buy” and a consensus target price of $11.67.

Insiders Place Their Bets

In other news, CEO Jerrell Shelton sold 4,620 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the transaction, the chief executive officer now directly owns 765,399 shares in the company, valued at $4,814,359.71. The trade was a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 19,830 shares of company stock worth $118,353 over the last three months. 10.10% of the stock is currently owned by company insiders.

Cryoport Stock Up 0.7 %

CYRX stock opened at $5.56 on Wednesday. The business’s 50-day moving average is $5.94 and its two-hundred day moving average is $6.98. The company has a market cap of $277.50 million, a price-to-earnings ratio of -1.64 and a beta of 1.81. Cryoport, Inc. has a fifty-two week low of $4.58 and a fifty-two week high of $17.41. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70.

Cryoport (NASDAQ:CYRX) last announced its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The business had revenue of $59.53 million for the quarter, compared to the consensus estimate of $58.71 million. During the same quarter last year, the firm posted ($0.29) earnings per share. As a group, analysts forecast that Cryoport, Inc. will post -0.99 earnings per share for the current year.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.